Your AI-Trained Oncology Knowledge Connection!
Dax Kurbegov, MD, was named vice president and physician-in-chief of clinical programs at Sarah Cannon in Nashville, Tennessee. He will oversee the expansion of Sarah Cannon’s cancer network, which sees more than 120,000 newly diagnosed cancer cases per year.
Jonathan Riess, MD, discusses the game-changing efficacy of osimertinib in NSCLC and its potential in combination, considering factors for choosing an EGFR TKI, and the burgeoning questions clinicians still have with the<em> EGFR</em>-mutant population.
Bradley J. Monk, MD, discusses his insight on the potential of immunotherapy in ovarian cancer, as well as what promise it might hold in other gynecologic malignancies.
An overview of FDA news that happened in April.
The PD-L1 inhibitor durvalumab has been granted an accelerated approval by the FDA for the treatment of patients with locally advanced or metastatic urothelial carcinoma.
Axel Grothey, MD, addresses the need for tailoring treatments for patients with mCRC in the first-line setting, the debate over tumor sidedness in mCRC, and what ongoing research in the field might reveal over the next year.
Rahmi Oklu, MD, PhD, sheds light on the various approaches physicians use to treat patients who have CRC with liver metastases.
Shitanshu Uppal, MD, discusses the critical challenges to research and treatment advances in cervical and endometrial cancer.
Shana Wingo, MD, discusses advancements being made in the field of surgery for patients with gynecologic cancers.
Daratumumab has been approved by the European Commission for use in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone for the treatment of patients with multiple myeloma following at least 1 prior therapy.
Wassim Abida, MD, PhD, discusses how genetic testing can benefit patients with prostate cancer and their families, and the challenges that still need to be addressed in this area.
Brigatinib has been granted an accelerated approval by the FDA as a treatment for patients with metastatic <em>ALK</em>-positive non–small cell lung cancer who are resistant to prior crizotinib.
Midostaurin (Rydapt) has been approved by the FDA for the treatment of adult patients with newly diagnosed <em>FLT3</em>-positive acute myeloid leukemia (AML) in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation.
Lorlatinib has been granted a breakthrough therapy designation by the FDA for use in patients with <em>ALK</em>-positive metastatic non-small cell lung cancer who have previously received 1 or more ALK inhibitors.
Regorafenib has been approved by the FDA as a second-line treatment for patients with unresectable hepatocellular carcinoma who have previously received sorafenib.
Bert O’Neil, MD, discusses the need for novel treatments for patients with metastatic colorectal cancer as well as why researchers need to develop a deeper understanding of tumor biology.
Osimertinib has been granted a full approval by the European Union for the treatment of patients with locally advanced or metastatic <em>EGFR T790M </em>mutation-positive non–small cell lung cancer, regardless of prior treatment with an EGFR TKI.
Amit Singal, MD, discusses the recent successes in the HCC treatment landscape and the challenges that still remain.
Matthew Gubens, MD, sheds light on how far the field has come with molecular testing, the challenges still ahead, and what novel assays could be on the horizon.
Stephen M. Ansell, MD, PhD, discusses emerging combinations being investigated in patients with mantle cell lymphoma, the possible role of immunotherapy, and challenges oncologists are still struggling with in this population.
Joshua Armenia, PhD, discusses an analysis that uncovered 23 genes that have not been previously identified as significantly mutated in prostate cancer.
Dana Chase, MD, discusses the potential for immunotherapy in recurrent endometrial cancer, as well as the lack of progress made thus far in endometrial cancer and other rare cancer types.
The treatment paradigm for HER2-positive breast cancer continues to focus on minimizing the role of chemotherapy and determining the optimal combination of HER2-targeted agents for specific patient subsets.
Immunotherapy has made a significant impact in the field of non–small cell lung cancer. However, as more research unravels, investigators are unsure which set of combinations will have the most positive effect on their patients with advanced disease.
Researchers at Dana-Farber Cancer Institute have identified an exceptional responder to pembrolizumab – a treatment-naïve patient with metastatic uterine leiomyosarcoma who had a complete tumor remission for more than 2 years on the PD-1 inhibitor.
The addition of abemaciclib to letrozole or anastrozole improved progression-free survival over either aromatase inhibitor alone in women with HR+/HER2-negative breast cancer enrolled in the phase III MONARCH 3 study.
According to an assessment of a large global dataset reported at the 2017 International Liver Congress, log<sub>10</sub> alpha fetoprotein level in the blood directly corresponded to the years of posttreatment survival in patients with hepatocellular carcinoma.
Patients with advanced hepatocellular carcinoma who were previously treated with sorafenib had long-term responses to nivolumab of more than 1 year.
In patients with hepatocellular carcinoma, liver-targeting treatment with selective internal radiation therapy more effectively controlled liver tumor progression and was better tolerated, but the therapy did not improve rates of overall or progression-free survival over sorafenib.
Mipsagargin, a first-in-class prodrug, showed promising antitumor activity and enabled patients with advanced sorafenib-refractory hepatocellular carcinoma to achieve disease stabilization.
